HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.

Abstract
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death. Epithalon prolonged the average and maximum lifetimes of mice by 13.5 (p<0.05) and 13.9%, respectively. The peptide prolonged the average lifetime of animals without neoplasms (by 34.2%, p<0.05). Epithalon decelerated the development of age-related disturbances in reproductive activity and suppressed the formation of neoplasms. The peptide decreased the incidence of breast adenocarcinomas, lungs metastases (by 1.6 times, p<0.05), and multiple tumors (by 2 times). Epithalon 3.7-fold increased the number of mice without breast tumors (p<0.05), while the number of animals with 6 or more breast tumors decreased by 3 times (p<0.05). Epithalon prolonged the lifetime of mice with breast tumors by 1.4 times (p<0.05). These results indicate that Epithalon possesses geroprotective activity and inhibits breast carcinogenesis in transgenic mice, which is probably related to suppression of HER-2/neu expression.
AuthorsV N Anisimov, V Kh Khavinson, I N Alimova, A V Semchenko, A I Yashin
JournalBulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 134 Issue 2 Pg. 187-90 (Aug 2002) ISSN: 0007-4888 [Print] United States
PMID12459848 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Oligopeptides
  • Receptor, erbB-2
  • alanyl-glutamyl-aspartyl-glycine
Topics
  • Adenocarcinoma (genetics, pathology)
  • Aging (drug effects)
  • Animals
  • Breast Neoplasms (genetics, pathology)
  • Mice
  • Mice, Transgenic
  • Oligopeptides (pharmacology)
  • Receptor, erbB-2 (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD